These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 35028610)

  • 21. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
    Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
    J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH1 and IDH2 mutations in gliomas.
    Cohen AL; Holmen SL; Colman H
    Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
    Liu X; Ling ZQ
    Histol Histopathol; 2015 Oct; 30(10):1155-60. PubMed ID: 26147657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
    Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
    Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consequences of
    Kaminska B; Czapski B; Guzik R; Król SK; Gielniewski B
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30857299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
    Schaap FG; French PJ; Bovée JV
    Adv Anat Pathol; 2013 Jan; 20(1):32-8. PubMed ID: 23232569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
    Fujiwara H; Tateishi K; Misumi K; Hayashi A; Igarashi K; Kato H; Nakatsuka T; Suzuki N; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Kogure H; Nakai Y; Isayama H; Hasegawa K; Fukayama M; Soga T; Koike K
    Sci Rep; 2019 Dec; 9(1):18859. PubMed ID: 31827136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
    Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
    Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
    Babakoohi S; Lapidus RG; Faramand R; Sausville EA; Emadi A
    Appl Immunohistochem Mol Morphol; 2017; 25(5):334-337. PubMed ID: 26945443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.
    Krell D; Mulholland P; Frampton AE; Krell J; Stebbing J; Bardella C
    Future Oncol; 2013 Dec; 9(12):1923-35. PubMed ID: 24295421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
    Laurenti G; Tennant DA
    Biochem Soc Trans; 2016 Aug; 44(4):1111-6. PubMed ID: 27528759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
    Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
    Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
    Wahl DR; Venneti S
    Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.